Stock · BIOCON · Healthcare
BIOCON share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for BIOCON LIMITED, refreshed every end-of-day run. A systematic, data-only read on BIOCON LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads BIOCON as constructive with a Crack Score of 78/100 as of 25 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 24 Jul 2026
Where BIOCON stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
25/100Money flow
68/100Result pulse · Q4 FY26
40/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
at/near 52w high (<=3% off)
RSI 57.7 (strong)
above a rising MA frame
not over-extended (<5 ATR over 50DMA)
Red flags
above 200DMA (not a confirmed short-side trend)
profit collapse (-56.77% YoY)
Relative valuation
P/E (TTM)
156.0P/E vs sector
+3.2%Sector percentile
98PEG
n/aScanner levels from the deterministic engine run of 2026-07-24, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 25 Jul 2026
Support and resistance for BIOCON are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the BIOCON chart, refreshed every end-of-day run.
The Crack Score, and how it is built78 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for BIOCON, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on BIOCON reads right now.
The editorial price read on BIOCON is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on BIOCON can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving BIOCON.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why BIOCON moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
BIOCON LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
40 / 100Revenue
Rs 4,517 crNet profit
Rs 199 crEPS (quarter)
Rs 0.79| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +2.3% | +8.2% |
| Net profit | -56.8% | +483.4% |
| Net margin | +4.4% | |
Figures are the Q4 FY26 result for BIOCON LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
BIOCON LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
BIOCON official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 4,517 cr | Rs 0.79 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 4,173 cr | Rs 1.08 | n/a | 32/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 4,296 cr | Rs 0.66 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 3,942 cr | Rs 0.26 | n/a | 50/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 4,417 cr | Rs 2.88 | n/a | n/a | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 3,821 cr | Rs 0.21 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 3,590 cr | Rs -0.13 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 3,433 cr | Rs 5.51 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 3,917 cr | Rs 1.13 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 3,954 cr | Rs 5.52 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 3,462 cr | Rs 1.05 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 3,423 cr | Rs 0.85 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 3,774 cr | Rs 2.62 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 2,941 cr | Rs -0.35 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 2,320 cr | Rs 0.39 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 2,140 cr | Rs 1.21 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 2,409 cr | Rs 2.00 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 2,174 cr | Rs 1.57 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 1,840 cr | Rs 1.16 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 1,761 cr | Rs 0.71 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 1,839 cr | Rs 2.13 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 1,851 cr | Rs 1.42 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 1,745 cr | Rs 1.43 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 1,671 cr | Rs 1.26 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 1,581 cr | Rs 1.04 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 1,748 cr | Rs 1.71 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 1,572 cr | Rs 1.82 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 1,466 cr | Rs 1.74 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 1,529 cr | Rs 3.61 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 1,541 cr | Rs 3.67 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 1,321 cr | Rs 6.00 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 1,124 cr | Rs 2.03 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
BIOCON LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
16,927 crNet profit (TTM)
369 crEBIT (TTM)
1,438 crProfit before tax (TTM)
448 crNet margin (TTM)
2.2%Finance costs (TTM)
990 crBalance sheet, as filed 2026-03-31
Total assets
63,651 crShareholder equity
36,622 crTotal borrowings
14,825 crCash and equivalents
2,417 crInventory
6,086 crTrade receivables
5,987 crThe cash engine, latest filed year
Operating cash flow
1,994 crCapex
1,912 crFree cash flow
82.3 crInvesting flow
-2,082 crFinancing flow
-924 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 16,927 cr | 369 cr | 36,622 cr | 14,825 cr | 1,994 cr |
| FY25 | 15,262 cr | 1,429 cr | 27,713 cr | 17,756 cr | 4,061 cr |
| FY24 | 14,756 cr | 1,298 cr | 25,275 cr | 15,730 cr | 2,954 cr |
| FY23 | 11,174 cr | 643 cr | 22,489 cr | 17,771 cr | 1,853 cr |
| FY22 | 8,184 cr | 772 cr | 9,470 cr | 4,904 cr | 1,177 cr |
| FY21 | 7,106 cr | 846 cr | 8,508 cr | 3,556 cr | n/a |
Every figure is parsed from BIOCON LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record22 earnings calls
Every BIOCON earnings call BazaarBaazi has indexed, latest 30 Jun 2026. Read management in its own words, straight from the filed transcript.
BIOCON LIMITED earnings calls on record
22 calls since 31 May 2021
Show 14 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from BIOCON LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
BIOCON LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
67 / 100Event Heat is a dated net read of BIOCON LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the BIOCON chart. Not a substitute for a registered research note.
| Ticker | BIOCON |
|---|---|
| Full name | BIOCON LIMITED |
| Sector | Healthcare |
| Index class | LARGE CAP |
| ISIN | INE376G01013 |
| Market-cap band | ~1.1 lakh cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | BIOCON |
Reference chartLevels in show
The daily frame the desk reads on BIOCON.
FAQ11 reader questions · AEO-eligible
The line on BIOCON, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the BIOCON share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on BIOCON. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for BIOCON?
The BazaarBaazi Crack Score for BIOCON is 78 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on BIOCON?
Strike-level option inventory for BIOCON is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is BIOCON in and which peers does BazaarBaazi track?
BIOCON sits in Healthcare (large cap), indicative market cap ~1.1 lakh cr (indicative), ISIN INE376G01013. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on BIOCON LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the BIOCON view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on BIOCON is bullish, published in Systematic Read on 21 Jul 2026.
Is BIOCON a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, BIOCON LIMITED sits in the Scanned tier with a setup score of 71/100 (technical 100, fundamental 25). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read BIOCON LIMITED's earnings call transcripts?
BazaarBaazi indexes 22 BIOCON earnings calls going back to 2021-05-31, latest 2026-06-30. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was BIOCON LIMITED's Q4 FY26 net profit?
BIOCON LIMITED reported a net profit of Rs 199 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -56.8% year on year. The figure is from the company's official NSE filing.
What was BIOCON LIMITED's Q4 FY26 revenue?
BIOCON LIMITED reported revenue of Rs 4,517 cr for Q4 FY26. That is +2.3% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate BIOCON LIMITED's Q4 FY26 result?
BazaarBaazi gives BIOCON LIMITED's Q4 FY26 result a Result Pulse of 40 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Biocon Ltd announced recently?
The most recent official filing on record for Biocon Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside BIOCON, each a living view refreshed every end-of-day run.